17 September 2018

CORPORATE MEDIA RELEASE

NEW AND EXCLUSIVE DISTRIBUTION AGREEMENT FOR ENDOCUFF VISIONTM IN EUROPE, MIDDLE EAST AND AFRICA

 

AMSTERDAM. The Netherlands / HAMBURG, Germany, 17 September, 14:00 CET. Arc Medical Design Limited (Arc), a subsidiary of Norgine B.V., and Olympus Europa announced today that they entered into a new distribution agreement by which Arc appoints Olympus Europa as the exclusive distributor of ENDOCUFF VISION in Europe, Middle East and Africa with immediate effect. Distribution in the UK will start in 2019.

 

ENDOCUFF VISION is a single use device attached at the distal end of the colonoscope that gives an optimal view of the entire colon by retracting folds during withdrawal.

 

 

ENDOCUFF VISION has shown to significantly improve adenoma detection rates and cancer detection rates and colorectal cancer detection during colonoscopy in bowel cancer screening patients[i]

  • ENDOCUFF VISION increased adenoma detection rate globally from 36.2% to 40.9% (P=0.02)i
  • A total of 56 colorectal cancers were detected in 36 patients when using ENDOCUFF VISION and in 20 patients during standard colonoscopy i.

 

Tas Javed, Managing Director at Arc said: “Olympus Europa offers great expertise in the endoscopic market, which I believe will help continue to promote the benefits of ENDOCUFF VISION with both doctors and patients in order to improve colorectal cancer detection.”

Harald Dremel, Director Medical Endoscopy Group at Olympus Europa agrees and adds: “We believe that combining the optical precision technology from Olympus with the new mechanical advantage ENDOCUFF VISION to improve adenoma detection rate represents an important advantage to our users and their patients.”

As of now, Olympus Europa will offer ENDOCUFF VISION to its customers throughout the EMEA region – including the UK from 2019. Norgine already distributes ENDOCUFF VISION in Australia, Olympus America in the USA and Canada: http://medical.olympusamerica.com/

For more product specific information about ENDOCUFF VISION in Europe, Middle East and Africa: http://endocuff.com/products/endocuff-vision/

ENDOCUFF VISION is a trademark of Arc Medical Design Limited.

 

About Norgine

 

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net product sales were EUR 345 million, up 17 per cent.

Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.

Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

 

Norgine is headquartered in the Netherlands.

 

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com

NORGINE and the sail logo are trademarks of the Norgine group of companies.


About Olympus

 

Olympus Europa is the headquarters for the region EMEA (Europe, Middle East and Africa) of the Olympus Corporation, Tokyo, Japan. As a worldwide leading manufacturer of optical and digital precision technology, Olympus provides innovative solutions for state-of-the-art medical systems, digital cameras as well as scientific solutions. The company’s award-winning products are instrumental in detecting, preventing and healing illness, driving scientific research and documenting life with artistic freedom. In the hands of its customers, Olympus’ high-tech products help to make people’s lives healthier, safer and more fulfilling.

For more information: olympus-europa.com

 

 

 

Media Contacts:


Norgine

Isabelle Jouin, Corporate Communciations: Tel: +441895826237

Follow us @norgine

Olympus

Matthias Gengenbach

Corporate Communications, Medical Systems

Olympus Europa SE & Co. KG

Tel.: +49 40 23773 5867

Email: matthias.gengenbach@olympus-europa.com

 

[i] Ngu WS, et al. Gut 2018;66:1–9. doi:10.1136/gutjnl-2017-314889